Vertex Pharmaceuticals moved to buy Crinetics Pharmaceuticals for $10 billion, picking up Crinetics’ commercial endocrinology portfolio and late-stage pipeline. The companies said the deal would provide Vertex with Crinetics’ launched drug Palsonify, which treats acromegaly, along with additional development programs including a late-stage therapy for congenital adrenal hyperplasia. At Crinetics, investors reacted sharply: Crinetics shares reportedly jumped 101% in after-hours trading after the announcement, reflecting how quickly the market is pricing in Vertex’s planned scale-up of commercial endocrinology assets. The transaction is positioned as Vertex’s largest acquisition in its history, with both boards approving and deal completion expected in the third quarter of 2026. Vertex’s strategy centers on converting late-stage assets into near-term revenue contribution—an approach that is increasingly influencing how large drugmakers allocate capital in specialty categories.